Australia - angielski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - metoclopramide hydrochloride, quantity: 10 mg - tablet, film coated - excipient ingredients: purified talc; stearic acid; macrogol 6000; pregelatinised maize starch; hypromellose; titanium dioxide; colloidal anhydrous silica; maize starch; microcrystalline cellulose - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation

Australia - angielski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - metoclopramide hydrochloride, quantity: 5 mg - tablet, film coated - excipient ingredients: maize starch; pregelatinised maize starch; titanium dioxide; microcrystalline cellulose; macrogol 6000; purified talc; hypromellose; stearic acid; colloidal anhydrous silica - in adults (20 years and over): as an adjunct to x-ray examination of the stomach and duodenum. to assist in intestinal intubation. to control nausea and vomiting associated with the following conditions: intolerance to essential drugs possessing emetic properties; uraemia; radiation sickness; malignant disease; postoperative vomiting; labour; infectious diseases. there is no clear benefit in motion sickness or other labyrinth disturbances. metoclopramide hydrochloride has been found useful in the management of gastric retention after gastric surgery. metoclopramide hydrochloride may be useful in the treatment of diabetic gastroparesis of mild to moderate severity. once control of diabetes has been established by diet and/or insulin, metoclopramide hydrochloride should be discontinued.,young adults: the use of metoclopramide hydrochloride in patients under 20 years should be restricted to the following situations: severe intractable vomiting of known cause. vomiting associated with radiotherapy and intolerance to cytotoxic drugs. as an aid to gastrointestinal intubation

Australia - angielski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - amlodipine besilate, quantity: 13.88 mg (equivalent: amlodipine, qty 10 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate - 1. hypertension amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor.,2. angina amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate - 1. hypertension amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor.,2. angina amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - amlodipine besilate, quantity: 13.88 mg (equivalent: amlodipine, qty 10 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate - 1. hypertension amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor.,2. angina amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate - 1. hypertension amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor.,2. angina amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - amlodipine besilate, quantity: 13.88 mg (equivalent: amlodipine, qty 10 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate - 1. hypertension amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor.,2. angina amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate - 1. hypertension amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor.,2. angina amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - amlodipine besilate, quantity: 13.88 mg (equivalent: amlodipine, qty 10 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate - 1. hypertension amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor.,2. angina amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs.

Australia - angielski - Department of Health (Therapeutic Goods Administration)

ipca pharma (australia) pty ltd - amlodipine besilate, quantity: 6.935 mg (equivalent: amlodipine, qty 5 mg) - tablet, uncoated - excipient ingredients: calcium hydrogen phosphate dihydrate; microcrystalline cellulose; colloidal anhydrous silica; sodium starch glycollate type a; magnesium stearate - 1. hypertension amlodipine is indicated for the first line treatment of hypertension and can be used as the sole agent to control blood pressure in the majority of patients. patients not adequately controlled on a single antihypertensive agent may benefit from the addition of amlodipine, which has been used in combination with a thiazide diuretic, beta adrenoceptor blocking agent or an angiotensin-converting enzyme inhibitor.,2. angina amlodipine is indicated for the first line treatment of chronic stable angina. amlodipine may be used alone, as monotherapy or in combination with other antianginal drugs.